These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo. Leland P; Taguchi J; Husain SR; Kreitman RJ; Pastan I; Puri RK Mol Med; 2000 Mar; 6(3):165-78. PubMed ID: 10965493 [TBL] [Abstract][Full Text] [Related]
43. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein. Joshi BH; Leland P; Silber J; Kreitman RJ; Pastan I; Berger M; Puri RK Br J Cancer; 2002 Jan; 86(2):285-91. PubMed ID: 11870521 [TBL] [Abstract][Full Text] [Related]
44. Cintredekin besudotox in treatment of malignant glioma. Mut M; Sherman JH; Shaffrey ME; Schiff D Expert Opin Biol Ther; 2008 Jun; 8(6):805-12. PubMed ID: 18476792 [TBL] [Abstract][Full Text] [Related]
45. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Kioi M; Husain SR; Croteau D; Kunwar S; Puri RK Technol Cancer Res Treat; 2006 Jun; 5(3):239-50. PubMed ID: 16700620 [TBL] [Abstract][Full Text] [Related]
46. Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin. Husain SR; Gill P; Kreitman RJ; Pastan I; Puri RK Mol Med; 1997 May; 3(5):327-38. PubMed ID: 9205948 [TBL] [Abstract][Full Text] [Related]
47. Therapeutic efficacy of Cintredekin Besudotox (IL13-PE38QQR) in murine lung fibrosis is unaffected by immunity to Pseudomonas aeruginosa exotoxin A. Rosada RS; Moreira AP; Frantz FG; Puri RK; Rahman A; Standiford TJ; Zárate-Bladés CR; Silva CL; Hogaboam CM PLoS One; 2010 Jan; 5(1):e8721. PubMed ID: 20090941 [TBL] [Abstract][Full Text] [Related]
48. Inhibition of proliferation and clonal growth of human breast cancer cells by interleukin 13. Serve H; Oelmann E; Herweg A; Oberberg D; Serve S; Reufi B; Mücke C; Minty A; Thiel E; Berdel WE Cancer Res; 1996 Aug; 56(15):3583-8. PubMed ID: 8758930 [TBL] [Abstract][Full Text] [Related]
49. Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors. Kawakami M; Kawakami K; Takahashi S; Abe M; Puri RK Cancer; 2004 Sep; 101(5):1036-42. PubMed ID: 15329913 [TBL] [Abstract][Full Text] [Related]
50. Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma. Mintz A; Gibo DM; Madhankumar AB; Debinski W J Neurooncol; 2003; 64(1-2):117-23. PubMed ID: 12952292 [TBL] [Abstract][Full Text] [Related]
51. Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme. Debinski W; Gibo DM; Slagle B; Powers SK; Gillespie GY Int J Oncol; 1999 Sep; 15(3):481-6. PubMed ID: 10427128 [TBL] [Abstract][Full Text] [Related]
52. STAT6: its role in interleukin 4-mediated biological functions. Takeda K; Kishimoto T; Akira S J Mol Med (Berl); 1997 May; 75(5):317-26. PubMed ID: 9181473 [TBL] [Abstract][Full Text] [Related]
53. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma. Kreitman RJ; Puri RK; Pastan I Cancer Res; 1995 Aug; 55(15):3357-63. PubMed ID: 7614471 [TBL] [Abstract][Full Text] [Related]
54. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model. Kawakami K; Husain SR; Kawakami M; Puri RK Mol Med; 2002 Aug; 8(8):487-94. PubMed ID: 12435859 [TBL] [Abstract][Full Text] [Related]
55. Apoptotic pathways of cell death induced by an interleukin-13 receptor-targeted recombinant cytotoxin in head and neck cancer cells. Kawakami M; Kawakami K; Puri RK Cancer Immunol Immunother; 2002 Feb; 50(12):691-700. PubMed ID: 11862421 [TBL] [Abstract][Full Text] [Related]
56. The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Kawakami K; Taguchi J; Murata T; Puri RK Blood; 2001 May; 97(9):2673-9. PubMed ID: 11313257 [TBL] [Abstract][Full Text] [Related]
57. Expression of high-affinity interleukin 4 receptors on murine sarcoma cells and receptor-mediated cytotoxicity of tumor cells to chimeric protein between interleukin 4 and Pseudomonas exotoxin. Puri RK; Ogata M; Leland P; Feldman GM; FitzGerald D; Pastan I Cancer Res; 1991 Jun; 51(11):3011-7. PubMed ID: 2032239 [TBL] [Abstract][Full Text] [Related]
58. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy. Shimamura T; Fujisawa T; Husain SR; Joshi B; Puri RK Clin Cancer Res; 2010 Jan; 16(2):577-86. PubMed ID: 20068108 [TBL] [Abstract][Full Text] [Related]
59. Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis. Jakubzick C; Kunkel SL; Puri RK; Hogaboam CM Immunol Res; 2004; 30(3):339-49. PubMed ID: 15531774 [TBL] [Abstract][Full Text] [Related]